Stock DNA
Pharmaceuticals & Biotechnology
SEK 51 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.27
-50.29%
1.28
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Jan 2025)
Net Profit:
-3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-37.94%
0%
-37.94%
6 Months
-42.01%
0%
-42.01%
1 Year
-62.7%
0%
-62.7%
2 Years
-88.55%
0%
-88.55%
3 Years
-72.33%
0%
-72.33%
4 Years
-96.68%
0%
-96.68%
5 Years
-97.4%
0%
-97.4%
Phase Holographic Imaging AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
36.23%
EBIT Growth (5y)
5.54%
EBIT to Interest (avg)
-9.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.40
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.73
EV to EBIT
-3.16
EV to EBITDA
-4.08
EV to Capital Employed
2.00
EV to Sales
3.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-63.28%
ROE (Latest)
-50.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jan'25 - QoQ
Jan'25
Oct'24
Change(%)
Net Sales
6.50
3.00
116.67%
Operating Profit (PBDIT) excl Other Income
-1.00
-2.80
64.29%
Interest
1.30
0.50
160.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.70
-3.70
27.03%
Operating Profit Margin (Excl OI)
-212.30%
-1,068.20%
85.59%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jan 2025 is 116.67% vs 130.77% in Oct 2024
Consolidated Net Profit
QoQ Growth in quarter ended Jan 2025 is 27.03% vs 37.29% in Oct 2024
Annual Results Snapshot (Consolidated) - Apr'24
Apr'24
Apr'23
Change(%)
Net Sales
10.50
9.90
6.06%
Operating Profit (PBDIT) excl Other Income
-13.40
-16.90
20.71%
Interest
3.60
2.80
28.57%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-20.20
-23.20
12.93%
Operating Profit Margin (Excl OI)
-1,612.10%
-2,055.80%
44.37%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2024 is 6.06% vs 20.73% in Apr 2023
Consolidated Net Profit
YoY Growth in year ended Apr 2024 is 12.93% vs 8.66% in Apr 2023
About Phase Holographic Imaging AB 
Phase Holographic Imaging AB
Pharmaceuticals & Biotechnology
Phase Holographic Imaging PHI AB (PHI) is a Sweden-based company active in the field of medical technology. It develops and markets time-lapse cytometers for clinical applications. The products use holographic microscopy technology, with image sensors capturing light information from objects, and computer processing the information to create visual image. It is also engaged in the development of related software. Its method allows to view and measure living cell over time, without disturbing or destroying it. PHI collaborates with cancer- and stem cell researchers, among others. The Company’s product portfolio includes HoloMonitor M3, a bench-top time-lapse cytometer, and HoloMonitor M4, allowing cell analysis in the cultivation incubator.
Company Coordinates 
Company Details
Scheelevagen 22 , LUND None : 223 63
Registrar Details






